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Introduction {#sec1}
============

In recent years a renewed focus on sexual dimorphic mechanisms of pain has emerged. It is now widely recognized that many key mechanisms driving persistent pain differ between males and females in both animals and humans ([@bib37], [@bib41], [@bib45], [@bib64]). Although time course and magnitudes of nociceptive hypersensitivity for a variety of pain conditions are often similar in females and males, the mechanisms responsible for this hypersensitivity and degree of chronicity are sex dependent ([@bib37], [@bib41], [@bib59], [@bib64], [@bib65]). Gonadal hormones, for instance, are known to be key contributors to sex differences in a variety of physiological and pathophysiological processes ([@bib28], [@bib42]). Human and animal studies of pain symptoms and severity have established correlations with the menstrual cycle, menopause, and alterations in gonadal hormone concentrations ([@bib1], [@bib25], [@bib34], [@bib63], [@bib69]).

Recent findings on sexual dimorphisms have demonstrated a role for spinal microglia in male-specific pain mechanisms ([@bib64]) and a T cell selective contribution to nociceptive transmission in females ([@bib60], [@bib65]), although other investigators have described T cells to be involved in protection and resolution of pain ([@bib32], [@bib33]). It is possible that a neuron-specific, sexually dimorphic pain mechanism also could be involved and mediated by gonadal hormone controlled signaling. A prime candidate for this potential mechanism is prolactin (PRL) and its receptor (Prlr), since responsiveness to PRL in a variety of cell types depends on sex, menstrual cycle phase, pregnancy status, and lactation ([@bib7], [@bib16], [@bib18], [@bib55]). PRL is involved in female-specific regulation of transient receptor potential (TRP) and other ligand-gated channels in sensory neurons ([@bib18], [@bib35], [@bib54]). Global ablation of PRL and Prlr leads to a substantial and female-selective reduction in postoperative and inflammatory heat hypersensitivity ([@bib51], [@bib54]) and mechanical hypersensitivity, but the latter effect is observed in male and female mice ([@bib51], [@bib54]). These studies demonstrate a clear role for PRL-Prlr signaling in pain hypersensitivity after injury, but the cells mediating these effects and the mechanisms generating female-specific nociceptive responses remain unknown.

The central goals of the work described here were to gain insight into whether Prlr expression in sensory neurons drives female-specific nociceptive responses to PRL and to understand how these female-specific effects emerge. We show that PRL signaling to Prlr expressed in sensory neurons at the level of peripheral and central terminals regulates female-specific hyperalgesia in several pain models. We also elucidate mechanisms responsible for PRL\'s female-selective actions in the regulation of pain. Gonadal hormones regulate cellular phenotypes via classic genomic and transient non-genomic signaling pathways ([@bib2], [@bib29], [@bib58]). However, surprisingly, our work points to a novel mechanism for sex-specific regulation of nociceptor plasticity that is dependent on selective and estrogen-dependent translation of *Prlr* mRNA in female DRG neurons. Overall, our work establishes sensory neuron participation of a major neuroendocrine hormone PRL in female-selective regulation of pain as well as a novel paradigm connecting sex- and gonadal hormone-dependent translational control that could be critical to understanding sexual dimorphism in many biological processes.

Results {#sec2}
=======

Exogenous PRL Induces Thermal and Mechanical Hypersensitivity in Females but Not in Males {#sec2.1}
-----------------------------------------------------------------------------------------

Exogenous fully processed and non-modified human PRL (PRL) generated in an expression system sensitizes a subset of mouse female sensory neurons ([@bib7], [@bib54]). Statistically significant sensitization in male sensory neurons is achieved with approximately a 40-fold higher concentration of PRL ([@bib54]). To establish if this major difference is also found *in vivo*, we evaluated whether PRL produces hyperalgesia in female and/or male mice. PRL injected into the hind paw (*ipl*) generated profound heat ([Figure 1](#fig1){ref-type="fig"}A) and mechanical hyperalgesia ([Figure 1](#fig1){ref-type="fig"}B) in a dose-dependent manner in estrus female mice (two-way ANOVA; heat - F (3, 40) = 13.4; P \< 0.0001; mechanical - F (3, 37) = 10.9; P \< 0.0001). As low as 0.1 μg PRL generated thermal and mechanical hyperalgesia in females, whereas 1 μg PRL injected in the contralateral paw did not produce an effect ipsilaterally (bars "*Cont*" on [Figures 1](#fig1){ref-type="fig"}A and 1B). This indicates that PRL-induced hyperalgesia involves peripheral (i.e., local) mechanisms. In contrast, for male mice, higher amounts of PRL (10 μg) produced heat (two-way ANOVA; P \< 0.0001; [Figure 1](#fig1){ref-type="fig"}A) but not mechanical hypersensitivity P = 0.1; [Figure 1](#fig1){ref-type="fig"}B).Figure 1Exogenous PRL-Induced Hypersensitivity in Female and Male Mice(A--D) PRL-induced heat (A and C) and mechanical (B and D) hypersensitivity was assessed at 1 h post-PRL-administration time point in male and estrous female mice. PRL was administrated into the hind paw (ipl; A and B) or intrathecal space of spinal cord (SC; C and D). PRL dosages (0.1, 1, or 10 μg) and sex of mice are indicated. Mechanical threshold was measured with the Dynamic Plantar Aesthesiometer. "*Cont*" indicates contralateral injection of 1 μg PRL and measurements of hyperalgesia in the ipsilateral hind paw.(E and F) PRL (1 μg) was injected *ipl* (intra-plantar; panel E) or *it* (intrathecal; panel F), and mechanical hypersensitivity was measured in males and females at different estrous phases (diestrus \[*Diestr*\], estrous \[*Estr*\], and proestrus \[*Proestr*\]). BL is baseline reading before PRL administration.Data are represented as mean ± SEM. Statistical test is regular two-way ANOVA with Tukey\'s post hoc test (n = 5--10; NS, non-significant; \*p \< 0.05; \*\*p \< 0.01; \#p \< 0.0001). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Administration of PRL into the spinal cord via intrathecal injection (*it*) also produced substantial heat ([Figure 1](#fig1){ref-type="fig"}C) and mechanical hypersensitivity ([Figure 1](#fig1){ref-type="fig"}D) predominantly in females (two-way ANOVA; heat - F (3, 51) = 14; P \< 0.0001; mechanical - F (3, 45) = 20.6; P \< 0.0001). Spinal PRL-induced hypersensitivity was not significant in male mice (two-way ANOVA; heat P = 0.1; mechanical P = 0.2; [Figures 1](#fig1){ref-type="fig"}C and 1D). Unbound PRL protein undergoes relatively fast degradation ([@bib21]). Consistent with this pharmacokinetic property, PRL (1 and 10 μg) injected in the hind paw ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B) or spinal cord ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D) of female mice produced significant heat and mechanical hypersensitivity for up to \~4 h (especially for high doses) and peaked at 1--2 h post administration.

Prolonged withdrawal of estrogen and progesterone in ovariectomized (OVX) females totally ablates PRL responsiveness in rats ([@bib18]). We evaluated whether PRL responsiveness depends on the estrous phase of mice. Intraplantar (*ipl*) or spinal cord (*it*) injection of PRL (1 μg) induced mechanical hypersensitivity in females but not in males ([Figures 1](#fig1){ref-type="fig"}E and 1F two-way ANOVA; peripheral - F (6, 48) = 9.7; P \< 0.0001; n = 5; [Figure 1](#fig1){ref-type="fig"}E; and spinal - F (6, 48) = 4.5; P = 0.0011; n = 5). PRL sensitivity was not affected by female estrous phases ([Figure 1](#fig1){ref-type="fig"}F). These results show that exogenous PRL delivered locally into the hind paw or spinal cord triggers 4-h-long-lasting pain hypersensitivity in a female-selective manner, but independent of female estrous phases.

Female-Selective Suppression of Postoperative Pain by Prlr Antagonist {#sec2.2}
---------------------------------------------------------------------

Incision surgery and inflammation up-regulates PRL in a sex-dependent fashion in the hind paw and especially spinal cord, where the larger magnitude of upregulation is found ([@bib51], [@bib62]). We used the specific Prlr antagonist, Δ1-9-G129R-hPRL (ΔPRL) ([@bib61]), which is a modified PRL that binds to and blocks the function of Prlr in rat, mouse, and human ([@bib11]), to evaluate the role of Prlr in the regulation of postoperative pain in female and male mice and rats. In estrus female mice at 1 day post incision, ΔPRL (5 μg) applied into the spinal cord by intrathecal injection (*it*) significantly reversed heat (two-way ANOVA; F (6, 44) = 8.2; P \< 0.0001; n = 4--5; [Figure S2](#mmc1){ref-type="supplementary-material"}A) and mechanical hypersensitivity (P = 0.014 at 60 min; P = 0.03 at 120 min; n = 5--6; [Figure S2](#mmc1){ref-type="supplementary-material"}B). In contrast, ΔPRL (5 μg) did not show antagonism of incision-induced heat and mechanical hypersensitivity in male mice ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). We did not escalate the dosage of ΔPRL, since at dosages \>25 μg, it could show agonistic properties ([@bib62]). However, 5 μg of ΔPRL did not exhibit agonistic or antagonistic properties on mice that underwent sham procedures ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2D).

Since peak effects were observed at 60 min post ΔPRL, we recorded vehicle and ΔPRL actions at 60 min post injection. Male and estrous females were injected with vehicle or ΔPRL into hind paws (*ipl*) at 1 day post incision. Heat hypersensitivity in females, but not in males, was significantly reversed with ΔPRL (two-way ANOVA; F (4, 31) = 9.4; P \< 0.0001; n = 4--5; [Figure 2](#fig2){ref-type="fig"}A). Mechanical hyperalgesia in males as well as females was not significantly affected by hind paw administration of ΔPRL (two-way ANOVA; F (4, 50) = 0.2; P = 0.9; [Figure 2](#fig2){ref-type="fig"}B). Spinal injection of ΔPRL substantially reversed both heat (two-way ANOVA; F (4, 41) = 12.6; P \< 0.0001; n = 4--6; [Figure 2](#fig2){ref-type="fig"}C) and mechanical hypersensitivity (F (4, 40) = 18.2; P \< 0.0001; n = 5--6; [Figure 2](#fig2){ref-type="fig"}D) in a female-selective fashion.Figure 2Suppression of Postoperative Pain by *Prlr* Antagonist in Female and Male MiceVehicle (Veh) or Prlr antagonist (5 μg; ΔPRL) was injected into hind paw (*ipl*) of male and estrous female mice at 1 day post incision (Inc) or sham procedures. Heat (A) and mechanical (B) hypersensitivity was assessed at 1 h post Veh/ΔPRL injection. Vehicle or ΔPRL (5 μg) was injected intrathecally (*it*) into spinal cord of male and estrous female mice at 1 day post incision or sham procedures. Heat (C) and mechanical (D) hypersensitivity was assessed at 1 h post Veh/ΔPRL injection. BL are baseline values before incision procedures. Procedures and animal sex are indicated below the x axis.Data are represented as mean ± SEM. Statistical test is regular two-way ANOVA with Tukey\'s post hoc test (NS, p \> 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; \*\*\*\*p \< 0.0001; n = 5--7). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

PRL actions could vary between species and PRL release from the pituitary depends on the estrous phase ([@bib21]), but exogenous PRL responsiveness at periphery and spinal cord of naive female mice is not dependent on the estrous phase ([Figures 1](#fig1){ref-type="fig"}E and 1F). Accordingly, we evaluated whether ΔPRL effects differ in diestrus (diestrus 1 and 2 combined) versus estrus female rats. Spinal (*it*) injection of ΔPRL (5 μg) at 1 day post incision significantly reversed postoperative mechanical hypersensitivity in diestrus and estrus female (two-way ANOVA; F (8, 60) = 6.5; P \< 0.0001; n = 5) but not in male rats ([Figure 3](#fig3){ref-type="fig"}A). The inhibition of mechanical hypersensitivity was more pronounced in estrus compared with diestrus female rats (two-way ANOVA; P = 0.011; [Figure 3](#fig3){ref-type="fig"}A). Our findings indicate that blockage of Prlr leads to female-selective inhibition of postoperative hypersensitivity, which depends on the site of Prlr antagonist action ([Figures 1](#fig1){ref-type="fig"}B versus 1D) and partially on the estrous phase ([Figure 3](#fig3){ref-type="fig"}A) but not the rodent species ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}A).Figure 3Effects of *Prlr* Antagonist and Agonist in Different Inflammatory Pain Models in Female and Male Rats and Mice(A) Vehicle (Veh) or ΔPRL (5 μg) was injected into spinal cord of male, diestrus female (D-female), or estrous female (E-female) rats at 1 day post incision surgery (POP) or sham procedures. Mechanical hyperalgesia was assessed with Dynamic Plantar Aesthesiometer at 1 h post Veh/ΔPRL injection. BL are baseline values. Statistical test is two-way ANOVA with Tukey\'s post hoc test (NS, p \> 0.05; \*p \< 0.05; \*\*\*\*p \< 0.0001; n = 5--6).(B) IL-6 (1 ng) was injected into hind paw, and vehicle or ΔPRL (5 μg) was injected approximately simultaneously into hind paw (*paw*) or spinal cord (*it*) of estrous female mice. Mechanical hyperalgesia was assessed at 1 h post IL-6/Veh or IL-6/ΔPRL co-injections. BL is baseline value. Data are represented as mean ± SEM. Statistical test is regular two-way ANOVA Bonferroni\'s post hoc test (NS, p \> 0.05; \*\*\*\*p \< 0.0001; n = 6).(C and D) In the model of hyperalgesic priming, 0.5 ng PRL produces mechanical hypersensitivity in IL-6 (0.1 ng)-primed females (panel C) but not males (panel D). RB is baseline. Statistical test is regular two-way ANOVA Bonferroni\'s post hoc test \*\*\*p \< 0.001; ^\#^ p \< 0.0001; n = 5).(E) IL-6 (1 ng) and vehicle or PRL (1 μg) were co-injected into the paw in estrous-phase female mice. Mechanical hyperalgesia was assessed at indicated time points. BL is baseline value. Data are represented as mean ± SEM. Statistical test is regular two-way ANOVA Bonferroni\'s post hoc test (\*\*p \< 0.01; \*\*\*p \< 0.001; ^\#^p \< 0.0001; n = 6).

Prlr Modulates Inflammatory Hypersensitivity in Female Mice {#sec2.3}
-----------------------------------------------------------

Inflammatory hypersensitivity was induced by hind paw injection of interleukin (IL)-6 ([@bib40]). Co-injection of IL-6 (1 ng; into the hind paw, *ipl*) and ΔPRL (5 μg; into the spinal cord, *it*) effectively inhibited mechanical hypersensitivity in female mice, whereas IL-6 and vehicle or ΔPRL co-administration into the hind paw did not produce anti-mechanical hypersensitivity effects (two-way ANOVA; F (2, 28) = 13.3; P \< 0.0001; n = 5--6; [Figure 3](#fig3){ref-type="fig"}B).

The concentration of endogenous PRL in serum of rodents could be increased up to 100 ng/mL during inflammatory conditions ([@bib51], [@bib62]). It could be presumed that inflammation will sensitize Prlr signaling. To evaluate this possibility, we used the hyperalgesic priming model ([@bib40]) and examined whether hind paw injection of PRL could precipitate hyperalgesic priming in mice primed with IL-6. IL-6 (0.1 ng) was injected into the hind paw and following hypersensitivity resolution (5 days post IL-6), PRL was injected into the same hind paw. Priming with IL-6 dramatically (\>100-fold) sensitized Prlr signaling wherein estrus female, but not male mice, showed hypersensitivity to as low as 0.5 ng PRL (two-way ANOVA; for females; F (3, 24) = 7; P = 0.0015; n = 5; [Figure 3](#fig3){ref-type="fig"}C and for males; F (3, 20) = 2.5; P = 0.085; n = 5; [Figure 3](#fig3){ref-type="fig"}D).

It is well documented that many inflammatory and idiopathic chronic pain conditions have 2- to 6-fold greater prevalence, chronicity, and symptom severity in women as compared with men ([@bib10], [@bib20], [@bib69], [@bib70]). Hence, we examined whether addition of exogenous PRL to IL-6 could alter chronicity and/or severity of mechanical hypersensitivity. Single co-administration of PRL (1 μg) and IL-6 (1 ng) into the hind paw resulted in a substantial increase in the duration of mechanical hypersensitivity compared with co-injection of vehicle and IL-6 into females (two-way ANOVA; F (14, 136) = 4.6; P \< 0.0001; n = 5--6; [Figure 3](#fig3){ref-type="fig"}E). However, PRL did not increase the severity (i.e., magnitude) of inflammatory hypersensitivity ([Figure 3](#fig3){ref-type="fig"}E). In summary, these results indicate that peripheral and spinal Prlr signaling is involved in modulation of inflammatory pain in females.

Sensory Neuronal Prlr Regulates Inflammatory Pain in a Female-Selective Fashion {#sec2.4}
-------------------------------------------------------------------------------

Prlr is expressed not only in sensory neurons but also in DRG fibroblasts and satellite glial cells, some immune cells, and possibly by intrinsic spinal cord neurons ([@bib8], [@bib24], [@bib52], [@bib50]). Here, we evaluated whether sensory neuronal Prlr is essential in female-selective regulation of chemical-induced, inflammatory, and neuropathic pain. To do so, we ablated the *Prlr* gene in the Nav1.8^+^ subset of sensory neurons (*Prlr* CKO). The *Prlr*^fl/fl^ line was generated by insertion of inverse lox sites around exon 5 ([@bib14]). Hence, cre-recombination ablates the gene and activates GFP in Nav1.8^+^ neurons ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). C*re*-recombination was verified by GFP mRNA expression that can be amplified from DRG RNA of *Prlr* CKO but not *Prlr*^fl/fl^ female mice ([Figure S3](#mmc1){ref-type="supplementary-material"}C). To show conditional ablation of Prlr protein in sensory neurons, we performed immunohistochemistry (IHC) on spinal cord sections with CGRP and Prlr antibodies. [Figure S3](#mmc1){ref-type="supplementary-material"}D shows that Prlr protein is eliminated in central terminals of the dorsal horn of spinal cord but not in other Prlr^+^ cells of Nav1.8^cre/-^/Prlr^fl/fl^ female mice. IHC was performed only in female mice, since Prlr antibodies do not reliably label DRG sensory neurons and central terminals in spinal cord of male mice, probably owing to low Prlr expression in males and/or low sensitivity of Prlr antibodies. As an additional test of the validity of our conditional deletion approach, we also tested sensitization of TRPV1 by exogenous PRL in female mice and found that 1 μg/mL PRL sensitizes capsaicin (CAP)-evoked CGRP release in *Prlr*^fl/fl^ but not Nav1.8^cre/-^/Prlr^fl/fl^ (Prlr CKO) spinal cord slices ([Figure S3](#mmc1){ref-type="supplementary-material"}E).

Ablation of *Prlr* gene in sensory neurons substantially and female-selectively reduced postoperative heat (two-way ANOVA; F (3, 40) = 5.2; P = 0.004; n = 5--8; [Figure 4](#fig4){ref-type="fig"}A) and mechanical hypersensitivity (F (3, 48) = 3.5; P = 0.021; n = 5--8; [Figure 4](#fig4){ref-type="fig"}B) at the 1-day post-incision time point. In *Prlr* CKO animals, IL-6-induced mechanical hypersensitivity was also significantly reversed in females (two-way ANOVA; F (3, 28) = 13.3; P \< 0.0001; n = 5) but in not males (P = 0.99; n = 5) at 3 h post-IL6 time point ([Figure 4](#fig4){ref-type="fig"}C). Examination of the time course of IL-6 hypersensitivity development showed that IL-6-induced heat (two-way ANOVA; F (4, 40) = 0.74; P = 0.57; n = 5) and mechanical hypersensitivity (F (4, 40) = 0.09; P = 0.99; n = 5) were equally well developed in *Prlr*^fl/fl^ and *Prlr* CKO male mice ([Figures 4](#fig4){ref-type="fig"}D and 4E). In contrast, IL-6-induced heat (two-way ANOVA; F (4, 30) = 3.8; P = 0.012; n = 5) and mechanical hypersensitivity (P = 0.011 at 1 h post IL-6; P = 0.004 at 3 h post IL-6; n = 5) were substantially lesser in *Prlr* CKO compared with *Prlr*^fl/fl^ females at all time points ([Figures 4](#fig4){ref-type="fig"}F and 4G).Figure 4Hypersensitivity in Inflammatory Pain Models in Sensory Neuronal Prlr CKO Male and Female Mice(A) Postoperative (POP) heat hypersensitivity was measured 1 day post incision in Prlr^fl/fl^ (lox; control) and Nav1.8^cre/-^/Prlr^fl/fl^ (CKO) female and male mice.(B) POP mechanical hypersensitivity was measured 1 day post incision in lox and CKO female and male mice.(C) IL-6 (1 ng)-induced mechanical hyperalgesia was measured 3 h post IL-6 (ipl) in lox and CKO female and male mice.For (A)--(C), Lox BL and CKO BL are baseline measurements in indicated mouse lines. For (A)--(C), data are represented as mean ± SEM and the statistical test is regular two-way ANOVA with Tukey\'s post hoc test (NS, p \> 0.05; \*p \< 0.05; \*\*p \< 0.01; \*\*\*\*p \< 0.0001; n = 5--7).(D and E) Development of IL-6-induced heat (D) and mechanical (E) hyperalgesia in Prlr LOX (control) and Prlr CKO male mice.(F and G) Development of IL-6-induced heat (F) and mechanical (G) hyperalgesia in Prlr LOX and Prlr CKO female mice. BL are baseline measurements in indicated mouse lines.For (D)--(G), data are represented as mean ± SEM and the statistical test is regular two-way ANOVA with Bonferroni\'s post hoc test (\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; \*\*\*\*p \< 0.0001; n = 5--6). See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

In a neuropathic model of chronic constriction injury (CCI), heat and mechanical hyperalgesia were similarly developed in *Prlr*^fl/fl^ and *Prlr* CKO males ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). CCI-induced hypersensitivity was slightly less pronounced in *Prlr* CKO compared with *Prlr*^fl/fl^ females ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). In a test of chemical nociception, mustard oil-induced hypersensitivity was quickly resolved (within 30 min) and identical in *Prlr*^fl/fl^ and *Prlr* CKO females ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F). Overall, these data show that sensory neuronal Prlr contributes to female-selective regulation of hypersensitivity in inflammatory pain models but may play a lesser role in neuropathic and chemical-induced pain models.

Prlr Isoform mRNA Expression by DRG Sensory Neuronal Subtypes in Females and Males {#sec2.5}
----------------------------------------------------------------------------------

Sensory neuronal Prlr signaling appears to be female-selective for *in vivo* ([Figure 4](#fig4){ref-type="fig"}) and *in vitro* models ([@bib18], [@bib54]). This suggests that *Prlr* mRNA should have predominant expression in female compared with male sensory neurons. *Prlr* mRNA is mainly expressed in a subset of medium- and small-sized peptidergic and CGRP^−^/trpV1^+^ sensory neurons of female and male mice ([@bib50]). Prlr^+^ medium-sized peptidergic neurons can be divided into two subpopulations: NPY2R^+^ and NPY2R^−^ ([@bib50]). Separate analysis of single-cell sequencing for female versus male data shows Prlr expression is at similar levels in Prlr^+^ sensory neuronal groups ([@bib50], [@bib71]). However, data on sex-dependent expressions of Prlr long (Prlr-L) and short (Prlr-S) isoforms in sensory neurons, which have distinct functions ([@bib7], [@bib8], [@bib21]), are not available. Accordingly, we examined Prlr-L and Prlr-S mRNA expression in sensory neurons using single-cell quantitative PCR (qPCR). We randomly collected single small or medium-sized *Prlr-cre*^+^ DRG neurons from female and male Prlr^cre/+^/Rosa26^LSL-tDTomato/+^ mice and performed real-time qPCR with Prlr-L, Prlr-S, as well as sensory neuronal marker CGRP, TRPV1, and NPY2R primer sets. Expression of GAPDH was used as a loading and normalization control. All visualized and collected *Prlr-cre*^+^ neurons contained Prlr-L and Prlr-S mRNA ([Figure 5](#fig5){ref-type="fig"}A). Statistical analysis showed that Prlr-L and Prlr-S mRNA were expressed at approximately similar levels in female and male neuron subtypes: CGRP^+^/TrpV1^+^, CGRP^−^/TrpV1^+^, CGRP^+^/NPY2R^−^, and CGRP^+^/NPY2R^+^ (for Prlr-L t = 0.1 df = 34; P = 0.92 and for Prlr-S t = 0.51 df = 36; P = 0.62; [Figures 5](#fig5){ref-type="fig"}B and 5C). These findings lead to the unexpected conclusion that there are not clear differences for Prlr-L and Prlr-S mRNA expression levels between sexes in a variety of *Prlr-cre*^+^ sensory neuronal subtypes.Figure 5Real-time Single Cell Quantitative PCR for *Prlr-L* and *Prlr-S* from *Prlr*-*cre*^+^ Female and Male DRG Neurons(A) Representative heatmap showing Ct values generated by single-cell RT-PCR from *Prlr*-cre^+^ female (F) and male (M) DRG neurons. Y axis shows amplified set of genes. X axis marks randomly picked cells for PCR. Values of ≥38 on the heatmap is considered as no amplification. Normalized mRNA expression levels of *Prlr-L* (B) and *Prlr-S* (C) isoforms in sensory neuronal groups. Groups for single *Prlr*-*cre*^+^ neurons from female and male mouse DRG are indicated on the x axis. Data are represented as mean ± SEM. Statistical test is unpaired t test (non-significant p \> 0.05; n = 6--32 depending on *Prlr*-*cre*^+^ neuronal group) for each sensory neuronal group.

Sex- and Estrogen-Dependent Regulation of Neuronal Excitability in Prlr-cre^+^ Nociceptors {#sec2.6}
------------------------------------------------------------------------------------------

We have shown that exogenous, unmodified 23 kDa-PRL is able to produce hypersensitivity in a female-selective manner ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}) and enhance excitability in female DRG neurons ([@bib52]). Hence, regulation of excitability is a valid, dependable measure for Prlr activity in DRG neurons. We investigated whether PRL could regulate neuronal excitability in *Prlr-cre*^*+*^ sensory neurons isolated from Prlr^cre/+^/Rosa26^LSL-tDTomato/+^ female and male mouse DRG and whether this regulation is reliant on estrogen (E2). For these experiments, only small-sized *Prlr-cre*^*+*^ neurons belonging to CGRP^+^/TrpV1^+^ or CGRP^−^/TrpV1^+^ groups were selected ([@bib50]), since it is challenging to reliably produce an action potential (AP) train in medium- to large-diameter DRG neurons using whole-cell current-clamp patch recordings. Initially, a single depolarizing pulse was applied to identify the *Prlr-cre*^*+*^ neuronal group on the basis of AP parameters that clearly distinguish CGRP^−^/TrpV1^+^ from CGRP^+^/TrpV1^+^ as well as from medium-sized CGRP^+^/TrpV1^-^/NPY2R^−^ and CGRP^+^/TrpV1^-^/NPY2R^+^ neurons ([@bib53], [@bib50]). CGRP^+^/TrpV1^+^ neurons could be further sub-grouped ([@bib53], [@bib71]). However, data from different CGRP^+^/TrpV1^+^ sub-types were grouped together, because additional recording are required to discriminate these CGRP^+^/TrpV1^+^ neuronal sub-types. As soon as the *Prlr-cre*^*+*^ neuronal subtype was defined, a ramp protocol was applied to evaluate how PRL (0.2 μg/mL) treatment (2--3 min) regulates excitability in *Prlr-cre*^*+*^ neurons.

PRL triggered an increase in excitability in vehicle-treated CGRP^+^/TrpV1^+^ and CGRP^−^/TrpV1^+^ *Prlr*-*cre*^+^ estrus female (one-way ANOVA; F (3, 26) = 7.9; P = 0.0007; [Figures 6](#fig6){ref-type="fig"}A, 6D, and 6E) but not male DRG neurons (one-way ANOVA; F (3, 16) = 1.3; P = 0.3; [Figure 6](#fig6){ref-type="fig"}B). Mean value of PRL-induced excitability was larger in *Prlr*-cre^+^ CGRP^+^/TrpV1^+^ compared with CGRP^−^/TrpV1^+^ DRG female neurons ([Figure 6](#fig6){ref-type="fig"}A). Some female CGRP^−^/TrpV1^+^ *Prlr-cre*^*+*^ neurons had a higher firing frequency upon first ramp application and showed only a short AP train "burst" after PRL treatment ([Figure 6](#fig6){ref-type="fig"}C). We did not analyze these neurons. This burst firing pattern is typical for sensitized C-nociceptors (or naive A-LTMR neurons) ([@bib31]). These data indicate that despite equal *Prlr-L* and *Prlr-S* mRNA expression in female and male DRG neurons, Prlr produces female-selective regulation of excitability in small-sized *Prlr-cre*^*+*^ DRG nociceptors. Moreover, these data provide strong independent support for the behavioral findings that sensory neuronal Prlr signaling contributes to mediation of pain in a female-specific manner ([Figures 1](#fig1){ref-type="fig"} and [4](#fig4){ref-type="fig"}).Figure 6Sex and Estrogen-dependent Regulation of PRL-induced Excitability of *Prlr*-cre^+^ DRG NeuronsExogenous PRL induces regulation of excitability in female (A) and male (B) DRG neurons. DRG neurons in culture were treated with vehicle (E2-) or 17β-estradiol (E2+; 1 μg/mL) for 6--36 h in culture. Y axis is change in action potential (AP) frequency (i.e., excitability) after treatment with vehicle or PRL. Data are represented as mean ± SEM. The statistical test is one-way ANOVA with Tukey\'s post hoc test separately for females or males and for vehicle- or E2-treated groups (\*p \< 0.05; \*\*p \< 0.01; n = 4--12). Examples of AP trains before and after treatment with PRL for 2--3 min are shown in female CGRP^−^/trpV1^+^ E2-treated DRG neurons (C); female CGRP^−^/trpV1^+^ vehicle-treated DRG neurons (D); female CGRP^+^/trpV1^+^ vehicle-treated DRG neurons (E); male CGRP^−^/trpV1^+^ E2-treated DRG neurons (F); and male CGRP^+^/trpV1^+^ E2-treated DRG neurons (G).

OVX females and males have very low PRL sensitivity in sensory neurons ([@bib18], [@bib54]). OVX females and males have substantially lower E2 serum levels than cycling females. Hence, we asked whether E2 treatment could enhance PRL sensitivity in female neurons and generate PRL responsiveness in male neurons. To test this possibility, DRG neurons in culture were maintained in the presence of 17β-estradiol (E2; 1 μg/mL) for 6--36 h. In such conditions (i.e., E2^+^), PRL (0.2 μg/mL) increased the excitability of male CGRP^+^/TrpV1^+^, *Prlr-cre*^*+*^ neurons (one-way ANOVA; F (3, 18) = 10.3; P = 0.0004; [Figures 6](#fig6){ref-type="fig"}B and 6G). However, E2 treatment did not change PRL sensitivity of male CGRP^−^/TrpV1^+^, *Prlr-cre*^*+*^ neurons ([Figures 6](#fig6){ref-type="fig"}B and 6F). Interestingly, according to single-cell sequencing data, estrogen receptor mRNA is absent in CGRP^−^/TrpV1^+^ (i.e., NP-3 group) male neurons ([@bib71]). E2 treatment for less than 6 h did not have any effect on male DRG neurons (Veh 1 ± 0.1 versus PRL 0.9 ± 0.2, n = 6, P = 0.9). E2 treatment of female DRG neurons did not substantially enhance the already existing PRL sensitivity of CGRP^+^/TrpV1^+^ and CGRP^−^/TrpV1^+^ *Prlr-cre*^+^ neurons (two-way ANOVA; variables are sensory neuronal groups and treatment with E2; F (3, 41) = 0.09; P = 0.99 \[for CGRP^+^/TrpV1^+^\]; P = 0.98 \[for CGRP^−^/TrpV1^+^\]; [Figure 6](#fig6){ref-type="fig"}A). These data show that Prlr activity in female DRG neurons does not undergo additional sensitization by E2 treatment and may explain the independence of PRL responsiveness from the estrous phase ([Figures 1](#fig1){ref-type="fig"}E and 1F). In summary, PRL increases excitability only in female DRG neurons and prolonged (≥6 h) E2 treatment establishes PRL responsiveness in male CGRP^+^/TrpV1^+^ but not CGRP^−^/TrpV1^+^ *Prlr-cre*^*+*^ neurons.

PRL Responsiveness in Prlr-cre^+^ Neurons Are Regulated by a Prlr mRNA Translation Mechanism {#sec2.7}
--------------------------------------------------------------------------------------------

Generation of PRL sensitivity in male DRG neurons by E2 treatment implies that E2 is responsible for the production of functional Prlr. In the classical pathway for nuclear receptors, E2 would increase male *Prlr* mRNA and in doing so generate functional Prlr in sensory neurons. To evaluate regulation of *Prlr* mRNA expression by E2, we performed *in vivo* E2 treatment/replacement of male as well as female mice according to a standard protocol ([@bib18], [@bib52]). Then, *Prlr-cre*^+^ neurons were counted in single-cell suspension or Prlr-L and Prlr-S mRNA expressions were quantified. E2 treatment did not significantly alter the percentage of *Prlr-cre*^*+*^ male DRG neurons (9.71 ± 0.34% for vehicle (E2^-^) versus 10.15 ± 0.68% for E2^+^, n = 3 independent mice for single-cell suspensions) suggesting that E2 has little impact on *Prlr* transcription. Similarly, E2 did not affect the percentage of *Prlr-cre*^*+*^ female neurons (10.2 ± 0.4% for E2^-^ versus 12.0 ± 0.5% for E2^+^, n = 3). Quantitative RT-PCR on DRG tissue from wild-type males showed that neither *Prlr-L* nor *Prlr-S* mRNA expression in DRG was substantially altered by *in vivo* E2 treatment (unpaired t test for Prlr-S: t = 0.1; df = 6; P = 0.9; for Prlr-L: t = 0.8; df = 6; P = 0.4; [Figure 7](#fig7){ref-type="fig"}A). Female DRG *Prlr-L* and *Prlr-S* mRNA expression levels were also not affected by E2 treatment (unpaired t test for Prlr-S: t = 1.4 df = 4; P = 0.2; for Prlr-L: t = 1.2 df = 4; P = 0.3; [Figure 7](#fig7){ref-type="fig"}B). Therefore, we find no evidence for E2 control of transcription of either Prlr isoform.Figure 7E2-controlled *Prlr* mRNA Transcription and Translation in Male and Female DRG Neurons(A and B) Expression of *Prlr-L* and *Prlr-S* mRNA in male (A) and female (B) DRG tissues that was isolated from mice *in vivo* treated with vehicle (E2^-^) or E2 (E2^+^) for 7 days. mRNA levels were assessed by quantitative RT-PCR. Data were analyzed by one-way ANOVA (n = 3--4).(C) Inhibition of PRL (1 μg)-induced mechanical hypersensitivity in female mice by spinal treatment for 1--72 h with translation inhibitor 4EGI-1 (10 μg). BL is baseline read before PRL and 4EGI-1 treatment. "None" is no treatment with 4EGI-1. Data were analyzed by one-way ANOVA with Tukey's post hoc test (NS, p \> 0.05; \*\*p \< 0.01; n = 5).(D) PRL (0.2 μg/mL)-induced increase in excitability in female *Prlr*-*cre*^+^ cultured DRG neurons pre-treated for 16--20 h with 4EGI-1 (1 μg/mL). Data are represented as mean ± SEM. Statistical test is regular two-way ANOVA with Tukey\'s post hoc test (variables are treatments with Veh/PRL and Media/4EGI-1; \*\*\*p \< 0.001; n = 4--8).(E) PRL (0.2 μg/mL)-induced excitability of male *Prlr*-*cre*^+^ DRG neurons pre-treated for 16--20 h with mixtures of indicated drugs. Data are represented as mean ± SEM. Statistical test is one-way ANOVA with Tukey\'s post hoc test (\*\*p \< 0.01; n = 6--13).See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

To this point our results reveal that: (1) sensory neuronal expressed Prlr regulates inflammatory pain in a female-selective manner, (2) prolonged (\>6 h) E2 treatment is required to confer PRL sensitivity in male DRG neurons without affecting *Prlr* mRNA expression levels, (3) Prlr mRNA level is similar between *Prlr-cre*^*+*^ neuronal groups in male and female mice, and (4) E2 treatment does not induce changes in *Prlr-L* or *Prlr-S* mRNA expression. These results lead us to conclude that female-selective regulation of inflammatory pain via Prlr signaling pathway and female-selective and E2-mediated control of PRL sensitivity are not due to transcriptional or post-translational regulation of Prlr function in DRG neurons. Accordingly, we examined whether translation regulation of *Prlr* mRNA could be the mechanism underlying female-selective and E2-controlled PRL responsiveness. To test this, we first estimated the half-life for Prlr protein function. Cap-dependent translation in the DRG and spinal cord was blocked by intrathecal injection of 4EGI-1 (10 μg). Intrathecal PRL (1 μg)-induced mechanical hypersensitivity was measured at 1--72 h post 4EGI-1 time points in female mice. PRL-induced hypersensitivity was assessed 1 h post PRL. PRL-triggered mechanical hypersensitivity became insignificant at \>24 h post 4EGI-1 (one-way ANOVA; F (6, 28) = 5; P = 0.0013; [Figure 7](#fig7){ref-type="fig"}C). From this we conclude that the half-life for Prlr functional protein is likely 16--20 h and that new functional Prlr protein is not readily produced when cap-dependent translation is blocked ([Figure 7](#fig7){ref-type="fig"}C).

To test this finding in an independent system, we evaluated the effects of 4EGI-1 on PRL sensitivity of female DRG neurons in culture. To do so, we first evaluated whether 12- to 24-h-long 4EGI-1 treatment affects AP properties and/or excitability. CGRP-cre^+^/TRPV1-GFP^+^ DRG neurons, which represent the CGRP^+^/TRPV1^+^ group, were selected from female reporter mice. Since transient effects of PRL in sensory neurons are mediated via PKCε-dependent mechanisms ([@bib7]), cultured DRG neurons were treated with 4EGI-1 for the indicated time ([Figure S5](#mmc1){ref-type="supplementary-material"}A) and then the increase in excitability by PMA (a PKC activator) was evaluated. 4EGI-1 had no adverse effect on AP properties and did not block PMA-induced hyperexcitability over a 16- to 20-h-long 4EGI-1 treatment (one-way ANOVA; F (3, 19) = 7.5; P = 0.0017; [Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Longer treatment led to an inhibition of PMA-induced excitability and distortion in AP shapes ([Figure S5](#mmc1){ref-type="supplementary-material"}A). The findings in [Figures 7](#fig7){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"} indicate that PRL-induced increase in *Prlr-cre*^*+*^ neuron excitability should be evaluated only during the 16- to 20-h pre-treatment window with 4EGI-1.

[Figure 7](#fig7){ref-type="fig"}D shows that 16- to 20-h-long 4EGI-1 pre-treatment resulted in a substantial inhibition of PRL responsiveness in female *Prlr-cre*^+^ neurons (two-way ANOVA; F (3, 19) = 13.4; P \< 0.0001). E2 conferred PRL sensitivity in male DRG neurons ([Figures 6](#fig6){ref-type="fig"}A and [7](#fig7){ref-type="fig"}E). We examined whether this E2 action depends on translation mechanisms in male neurons. A 16- to 20-h-long pre-treatment of male *Prlr-cre*^+^ DRG neurons with a mix of E2 and 4EGI-1 (1 μg/mL each) totally blocked E2-dependent establishment of PRL sensitivity in these neurons ([Figure 7](#fig7){ref-type="fig"}E). These findings support the hypothesis that sex dimorphism in Prlr functional expression and consequently PRL responsiveness involve translation control mechanisms in DRG neurons wherein *Prlr* mRNA in male neurons is not effectively translated into functional protein owing to E2-driven control of a translational machinery.

To provide additional *in vivo* evidence for this hypothesis, we examined the relative presence of *Prlr* mRNA and protein in DRG neuron central terminals of males and females. We focused on central terminals because our behavioral findings had the largest magnitudes with intrathecally delivered treatments. IHC was conducted on spinal cord sections from male and female *Prlr*^cre/+^/Rosa26^LSL-tDTomato/+^ mice ([Figure 8](#fig8){ref-type="fig"}A). *Prlr* mRNA reporter expression in *Prlr-cre*^+^ fibers (red) was very similar in females and males (un-paired t test; t = 1.2 df = 4; P = 0.3; n = 3; background is subtracted and data normalized per measured area; [Figure 8](#fig8){ref-type="fig"}B), whereas Prlr protein detected by polyclonal anti-Prlr antibodies was substantially greater in females than in males in the dorsal horn (one-way ANOVA; F (2, 12) = 14.9; P = 0.0006; n = 3; [Figure 8](#fig8){ref-type="fig"}C). Similarly, female-predominant expression of Prlr protein was observed in spinal cord of rats using mouse monoclonal anti-Prlr (U5) antibodies (un-paired t test; t = 3 df = 4; P = 0.042; n = 3; [Figures 8](#fig8){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}). Taken together, these findings support the conclusion that the female-selective regulation of inflammatory pain by sensory neuronal Prlr and PRL sensitivity found in the DRG is due to translational regulation of Prlr function in sensory neurons.Figure 8*Prlr* mRNA Reporter Expression and Prlr Protein Localization in Female and Male Mouse Spinal Cord(A) IHC with Prlr antibodies (polyclonal) and CD68 (rat monoclonal) on spinal cord sections from Prlr^cre/+^/Rosa26^LSL-tDTomato/+^ female and male mice.(B) Intensity of TdTomato (Prlr-cre) labeling in spinal cord of female and male Prlr^cre/-^/TdTomato mice.(C) Intensity of Prlr protein (Prlr-ab) labeling in spinal cord of female and male Prlr^cre/-^/TdTomato mice. *Bgr* is normalized intensity of background.(D) Intensity of Prlr protein (Prlr-ab) labeling in spinal cord of female and male rats. A representative scale bar of 50 μm is shown.Data are represented as mean ± SEM. Statistical test is unpaired t test (B and D) or one-way ANOVA with Tukey\'s post hoc test (panel C) (NS, p \> 0.05; \*p \< 0.05; \*\*p \< 0.01; n = 3). See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Studies in animals and humans demonstrate clear sex dimorphisms in mechanisms that control development of chronic pain ([@bib17]), and the existing paradigm is that these dimorphisms are directly or indirectly regulated by gonadal hormones ([@bib69]). A growing body of research suggests that an important mechanistic difference between development of chronic pain in male and female mice is that distinct immune cells are critical drivers, microglia in males ([@bib49], [@bib64], [@bib65], [@bib67]) and T cells in females ([@bib65]). The male-specific microglia effects are conserved for mice and rats ([@bib36]) and can be conferred to females with testosterone treatment ([@bib65]). On the other hand, the T cell findings are controversial because T cells also play a critical role in pain resolution in some pain models ([@bib32], [@bib33]). Several recent studies have also found sex differences in mRNA expression using RNA sequencing in whole human DRG and tibial nerve ([@bib45], [@bib57]). The DRG transcriptomic work suggests that of the monocyte lineage in DRG and nerves may play a critical role in promoting neuropathic pain in males but to a lesser extent in females ([@bib45]). Sex differences in the tibial nerve transcriptomes, although not directly related to chronic pain since the tissues were from organ donors and not patients, found a clear signature for gonadal hormones in regulating transcriptomes in this tissue across the lifespan in females ([@bib57]). Collectively, these findings in rodents and humans support the classical viewpoint that gene regulation via gonadal hormone nuclear receptor-mediated transcription control mechanisms is a cornerstone of sex-dependent processes ([@bib48]) including sex dimorphisms in pain ([@bib59]). Our findings suggest a new twist on this paradigm wherein gonadal hormones could also regulate sensory neuron excitability via regulation of translation machinery or transcription of proteins belonging to the translation complex. As a key example, we demonstrated this mechanism for female-selective *in vitro* and *in vivo* PRL responsiveness in sensory neurons.

Previous studies showed gonadal hormones-dependent regulation of Prlr in non-neuronal cells ([@bib22], [@bib26], [@bib27], [@bib66]), but this is the first demonstration of such an effect in sensory neurons. Since Prlr does not have classical gonadal hormone-response element ([@bib48]), *Prlr* mRNA expression is thought to be regulated by E2 utilizing alternative transcription binding sites, such as C/EBP, Sp3, and/or Sp1A ([@bib19], [@bib23]). Based on the literature, it could be extrapolated that *Prlr* mRNA should be predominantly expressed in female DRG neurons in an estrogen-dependent fashion. However, surprisingly, our data, which were generated by multiple, independent methods, show that *Prlr-L* and *Prlr-S* mRNA expression in sensory neuronal subtypes are not sex- or E2-dependent. Post-translational (i.e., phosphorylation, glycosylation) regulation is also unlikely, since prolonged E2 treatment (\>6 h) is required for establishing PRL sensitivity in male neurons despite expression of *Prlr* mRNA. Our data support the conclusion that translation regulation of Prlr function is critical for the observed dimorphisms in nociceptive processes during inflammatory pathological pain conditions. Accordingly, inhibition of *cap*-dependent translation almost entirely ablated PRL responsiveness in *Prlr-cre*^*+*^ female neurons and blocked the behavioral response to PRL *in vivo*. In further support of this model, we showed that blockage cap-dependent translation eliminated E2-established PRL responsiveness in male DRG neurons. Moreover, we also observed robust expression of *Prlr-cre*^+^ sensory neurons and fibers in both male and female mice but found substantially higher Prlr protein expression in female rodent (rat and mice) spinal cord.

Based on these findings, we propose that sex- and E2-dependent translational regulation could be a novel mechanism for sexual dimorphism observed in many pain conditions ([@bib20]). This is especially relevant considering that translation control mechanisms are already known to strongly contribute to modulation and sensitization of nociceptors but suggests that therapeutic targeting of these mechanisms may have additional benefits in females ([@bib30], [@bib39]). Gonadal hormone-controlled translational regulation has been a subject of speculation but not studied in detail ([@bib13], [@bib46]). This mechanism could be due to an increase of efficiency of translation by gonadal hormones and/or gonadal hormone-controlled additional mRNA transcription of proteins involved in translational machinery. Thus, translation regulation factors encoded by *Eif2s3y* and *Eif2s3x* genes exhibit strong sex dependency in mRNA expression in many types of neurons ([@bib4], [@bib57]). E2-driven translational control over the suppressor of cytokine signaling (SOCS) protein family has been proposed ([@bib3], [@bib38]) where E2 can affect the translational machinery via mTOR phosphorylation ([@bib5]) and regulation of Rheb signaling ([@bib56]). Translation can also be controlled by factors binding to mRNA. One of such factors is Musashi (*Msi-1* and 2 genes), which binds specific sequences in the 3′ untranslated region (UTR) of mRNA and controls translation of proteins. It was shown that leptin can control translation of proteins by regulating Msi-1 expression ([@bib47]). These signaling pathways also play key roles in pain sensitization whereby they control the on-demand synthesis of new proteins that alter the excitability of nociceptors ([@bib30], [@bib43]).

A corollary of our work is that molecules involved in sex-dependent regulation of nociceptive pathways could be (1) induced by injury, (2) controlled by gonadal hormones, and (3) capable of regulating many other genes. PRL and its receptor Prlr fit these requirements. First, Prlr-mediated PRL effects are sex dependent in many tissues and cell types ([@bib7], [@bib8], [@bib51], [@bib68]). It is well documented that PRL responsiveness is closely controlled by E2 and to a lesser extent progesterone. Many clinical and preclinical studies also show that stress related to injury and inflammatory conditions trigger PRL release not only from the pituitary ([@bib15], [@bib44], [@bib72]), but also from extra-pituitary tissues, such as cells in skin and in the spinal cord ([@bib9], [@bib51], [@bib62]). Finally, Prlr activation could lead to epigenetic changes and transcription regulation of many genes via the STAT5 pathway ([@bib8], [@bib12]). This downstream transcriptional control may lead to additional diversification of nociceptor responses to injury since this pathway would not be induced in male neurons, which have very low levels of Prlr functional protein in most sensory neuronal types. The preponderance of data on sex-specific mechanisms of chronic pain has focused on male rodents. To our knowledge, this is one of the first demonstrations of a female-specific inflammatory pain mechanism acting directly on the sensory neuron. Interestingly, the discovery of a far greater potency of calcitonin gene related peptide (CGRP) in producing migraine pain-like behaviors in female mice also involves a peptide with intimate connections to nociceptor biology ([@bib6]).

In conclusion, our data demonstrate that sensory neuronal Prlr contributes to female-selective regulation of hypersensitivity in inflammatory pain models via local and spinal mechanisms. Sex dependency of PRL responsiveness and the generation of hypersensitivity by this mechanism in sensory neurons is likely controlled via translation mechanisms. We favor the hypothesis that sex-specific regulation of sensory neuronal excitability by PRL is governed via E2-controlled translation regulation of *Prlr* mRNA, and this in turn explains female-selective mechanisms for regulation of PRL-induced hypersensitivity in non-injured animals and inflammatory pain by sensory neuronal Prlr. These results add a new layer to our understanding of sex dimorphisms in pain signaling and further substantiate the critical role that translation regulation plays in setting nociceptor excitability in response to a broad variety of important physiological stimuli.

Limitations of Study {#sec3.1}
--------------------

PRL responsiveness in humans is influenced by the menstrual phases ([@bib21]). Unfortunately, data obtained in different estrous phases of rodent females ([Figures 1](#fig1){ref-type="fig"}E, 1F, and [3](#fig3){ref-type="fig"}A) do not translate well to human menstrual phases. There are several reasons for this lack of direct translation. First, the full estrous cycle in rodents is only 4--5 days. Therefore, stable proteins, such as Prlr ([Figure 7](#fig7){ref-type="fig"}C), synthesized in the previous estrous phase may still be present in the subsequent phase. Thus, in the diestrus phase, some of Prlr synthesized in estrous is still functional. Second, changes in patterns and levels of estrogen and progesterone from one phase to another are different for menstrual versus estrous cycles. This could influence Prlr synthesis. Another limitation of our study is the lack of currently available tools to separately study effects mediated by Prlr-L or Prlr-S isoforms. There are no reliable and validated antibodies labeling Prlr-L or Prlr-S, and mouse lines targeting only Prlr-S do not exist. Moreover, there are several Prlr-S isoforms ([@bib21]). Therefore, our work is unable to address questions related to short- versus long-term effects of Prlr signaling that are mediated by these different isoforms.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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